Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma announced mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.
Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma announced mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.